Description and Composition of Miorilas
Uses and Indications of MiorilasMiorilas is indicated as an adjunctive therapy for the relief of discomfort associated with acute painful musculoskeletal conditions. Methocarbamol is also indicated for control of muscle spasm in tetanus
Dosage and Administration of Miorilas
For Oral use in adultInitial: 1.5 g of miorilas is taken qds or 4 times daily Maintenance: 1 g qds or 4 times daily. For the first 48 to 72 hours, 6 g per day is recommended. For severe conditions, 8 g daily in divided doses may be administered and thereafter reduced to approximately 4 g or as directed by physician
Usage of Miorilas in TetanusMiorilas does not replace the usual procedure of tracheotomy, debridement, tetanus antitoxin, penicillin etc used in the treatment of tetanus. Rather, methocarbamol injection is added to this regimen.
Pharmacology and Mechanism of Action of Miorilas
Pharmacokinetics of MiorilasMiorilas is rapidly absorbed from the gastrointestinal tract following oral administration. Methocarbamol has an onset of action of 30 minutes. Peak plasma levels occur approximately 2 hours after administration of 2 gm. The half life is from 1 to 2 hours. Methocarbamol is metabolized, probably in the liver and excreted in urine primarily as the glucuronide and sulphate conjugates of its metabolites. A Small amount is excreted in faeces.
Side Effects of Miorilas
- Rash conjunctivitis with nasal congestion
- Blurred vision
Precautions, Warnings and Use during Pregnancy
- Miorilas may impair concentration, patients so affected should not drive or operate machinery
- Methocarbamol is not recommended during pregnancy, especially during early pregnancy or in women who may become pregnant, unless potential benefits outweigh potential hazards.
- It is not known whether methocarbamol is excreted in breast milk. Exercise caution when administering to nursing women.
- Safety and efficacy of methocarbamol in children below 12 yrs. Old has not been established, except
Miorilas Overdosage and its Treatment
Contraindications of MiorilasMiorilas is contraindicated in hypersensitive patients, in coma or pre-coma states, brain damage, myasthenia gravis or in patients with a history of epilepsy.
Miorilas Drug Interactions
Storage of MiorilasMiorilas tablets, suspension and powder for injection should be stored in a cool place below 25 °C. They should be protected from light. Keep every medicine out of reach of children.
Do you need to know more about your drugs?
Do you have a need to talk to a pharmacist?
Then use the button below to chat a pharmacist